359 related articles for article (PubMed ID: 33896016)
21. LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling.
Liu J; Xu R; Mai SJ; Ma YS; Zhang MY; Cao PS; Weng NQ; Wang RQ; Cao D; Wei W; Guo RP; Zhang YJ; Xu L; Chen MS; Zhang HZ; Huang L; Fu D; Wang HY
Theranostics; 2020; 10(17):7527-7544. PubMed ID: 32685003
[TBL] [Abstract][Full Text] [Related]
22. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
23. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
[TBL] [Abstract][Full Text] [Related]
24. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
25. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
26. Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
Zhu K; Shao J; Tao H; Yan X; Luo C; Zhang H; Duan W
J Comput Aided Mol Des; 2019 Aug; 33(8):775-785. PubMed ID: 31312965
[TBL] [Abstract][Full Text] [Related]
27. Induction of GNMT by 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranoside through proteasome-independent MYC downregulation in hepatocellular carcinoma.
Kant R; Yen CH; Hung JH; Lu CK; Tung CY; Chang PC; Chen YH; Tyan YC; Chen YA
Sci Rep; 2019 Feb; 9(1):1968. PubMed ID: 30760754
[TBL] [Abstract][Full Text] [Related]
28. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
29. β-Arrestin1 enhances hepatocellular carcinogenesis through inflammation-mediated Akt signalling.
Yang Y; Guo Y; Tan S; Ke B; Tao J; Liu H; Jiang J; Chen J; Chen G; Wu B
Nat Commun; 2015 Jun; 6():7369. PubMed ID: 26077142
[TBL] [Abstract][Full Text] [Related]
30. PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression.
Liu M; Yao B; Gui T; Guo C; Wu X; Li J; Ma L; Deng Y; Xu P; Wang Y; Yang D; Li Q; Zeng X; Li X; Hu R; Ge J; Yu Z; Chen Y; Chen B; Ju J; Zhao Q
Theranostics; 2020; 10(10):4437-4452. PubMed ID: 32292506
[TBL] [Abstract][Full Text] [Related]
31. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
Frau M; Feo F; Pascale RM
J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
[TBL] [Abstract][Full Text] [Related]
32. Aurora kinase A mediates c-Myc's oncogenic effects in hepatocellular carcinoma.
Lu L; Han H; Tian Y; Li W; Zhang J; Feng M; Li Y
Mol Carcinog; 2015 Nov; 54(11):1467-79. PubMed ID: 25284017
[TBL] [Abstract][Full Text] [Related]
33. NF-κB/mTOR/MYC Axis Drives PRMT5 Protein Induction After T Cell Activation via Transcriptional and Non-transcriptional Mechanisms.
Webb LM; Narvaez Miranda J; Amici SA; Sengupta S; Nagy G; Guerau-de-Arellano M
Front Immunol; 2019; 10():524. PubMed ID: 30941147
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype.
Orben F; Lankes K; Schneeweis C; Hassan Z; Jakubowsky H; Krauß L; Boniolo F; Schneider C; Schäfer A; Murr J; Schlag C; Kong B; Öllinger R; Wang C; Beyer G; Mahajan UM; Xue Y; Mayerle J; Schmid RM; Kuster B; Rad R; Braun CJ; Wirth M; Reichert M; Saur D; Schneider G
JCI Insight; 2022 May; 7(10):. PubMed ID: 35439169
[TBL] [Abstract][Full Text] [Related]
35. STK33 promotes hepatocellular carcinoma through binding to c-Myc.
Yang T; Song B; Zhang J; Yang GS; Zhang H; Yu WF; Wu MC; Lu JH; Shen F
Gut; 2016 Jan; 65(1):124-33. PubMed ID: 25398772
[TBL] [Abstract][Full Text] [Related]
36. Regulation of glycosylphosphatidylinositol-anchored proteins and GPI-phospholipase D in a c-Myc transgenic mouse model of hepatocellular carcinoma and human HCC.
Ritorto MS; Rhode H; Vogel A; Borlak J
Biol Chem; 2016 Nov; 397(11):1147-1162. PubMed ID: 27232633
[TBL] [Abstract][Full Text] [Related]
37. Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells.
Mongiardi MP; Savino M; Bartoli L; Beji S; Nanni S; Scagnoli F; Falchetti ML; Favia A; Farsetti A; Levi A; Nasi S; Illi B
Sci Rep; 2015 Nov; 5():15494. PubMed ID: 26563484
[TBL] [Abstract][Full Text] [Related]
38. FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1.
Shi W; Feng L; Dong S; Ning Z; Hua Y; Liu L; Chen Z; Meng Z
Cell Commun Signal; 2020 Jun; 18(1):100. PubMed ID: 32576198
[TBL] [Abstract][Full Text] [Related]
39. MYC-regulated genes involved in liver cell dysplasia identified in a transgenic model of liver cancer.
Hunecke D; Spanel R; Länger F; Nam SW; Borlak J
J Pathol; 2012 Dec; 228(4):520-33. PubMed ID: 22653869
[TBL] [Abstract][Full Text] [Related]
40. PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy.
Yu M; Chen Z; Zhou Q; Zhang B; Huang J; Jin L; Zhou B; Liu S; Yan J; Li X; Zhang W; Liu C; Hu B; Fu P; Zhou C; Xu Y; Xiao Y; Zhou J; Fan J; Ren N; Hung MC; Guo L; Li H; Ye Q
J Hepatol; 2022 Jul; 77(1):140-151. PubMed ID: 35157958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]